NEWS RELEASE

Viridian Therapeutics to Participate in the 9th Annual Evercore Healthcare Conference

2026-11-24

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference at 8:20am ET on Tuesday, December 1, 2026, in Coral Gables, Florida.

A live webcast of the fireside chat can be accessed under “Events & Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available after the event on the Viridian website.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes.

With an immediate focus in thyroid eye disease (TED), we developed Lumvoa™, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.

Viridian is headquartered in Waltham, Massachusetts. For more information, please visit **www.viridiantherapeutics.com**. Follow Viridian on **LinkedIn** and **X**.

Investors
Greg Rossino
grossino@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.